(Shenzhen/Hong Kong) — On November 28, Shenzhen Cell Valley Biomedical Co., Ltd. (SZCV) announced the formal signing of a Memorandum of Cooperation (MoC) with Hong Kong Institute of Cell and Gene Therapy Limited (HKICGT) to jointly establish a joint venture in Hong Kong. This marks a pivotal step for Shenzhen Cell Valley in advancing the   internationalization, standardization, and commercialization of cell and gene therapy (CGT).It also means that the clinical-grade cell products independently researched and manufactured in Shenzhen will launch a more comprehensive strategic layout in the Hong Kong and global markets.

As one of the first enterprises in China to obtain access to the “white list” channel for the entry and exit of cell products,Shenzhen Cell Valley has established a full cross-border chain capability covering the import of leukapheresis products into the Chinese mainland and the export of various cell products to Hong Kong. This cooperation will further leverage the institutional strengths of “two-way opening and dual-hub connectivity” between Shenzhen and Hong Kong, helping global innovative technologies achieve faster transformation and implementation in the Guangdong-Hong Kong-Macao Greater Bay Area.

· GMP International Standard Biomanufacturing Platform: Supports the development and production of comprehensive system products including vectors, gene editing tools, CAR construction, immune cells, stem cells, and exosomes

· Cross-border Clinical Research Hub: Serving Hong Kong public hospitals and international research institutions to accelerate IIT and translational medicine research

·A global CGT technology export center: building an open platform linking China's innovation with international partners

·Longevity Medicine and Regenerative Medicine Demonstration Center: Covering core areas such as anti-aging, cancer, diabetes, autoimmune diseases, neurodegenerative diseases, cardiovascular and orthopedic diseases

Dr. David Kin Jin, Director of the Hong Kong Institute for Cell and Gene Therapy, also stated: "Hong Kong serves as a strategic gateway to the global market, while Shenzhen Cell Valley leads in the manufacturing and technological platforms for CGT. This collaboration will jointly accelerate the development of next-generation cell and gene therapies in the Asian region."

Mr.David Hui, Chairman of the Board of HKICGT, stated: 'The purpose of this collaboration is to establish Hong Kong's largest, highest-standard, and most comprehensive cell and gene therapy product manufacturing center, benefiting the citizens of Hong Kong.'

Professor Shi Yuanyuan, Chairman of Shenzhen Cell Valley, stated: "Hong Kong possesses institutional advantages for global connectivity, while Shenzhen has comprehensive capabilities in the CGT industry chain. The collaboration between the two parties represents the optimal combination for the Greater Bay Area to achieve 'origin innovation + manufacturing capacity + international clinical hub'."

The signing ceremony was attended by Professor Lo Yuk-lam, President of the Hong Kong Biomedical Innovation Association and 'Father of Hong Kong Biotechnology'; Dr. Maggie Lo, Director of the Office for Attracting Key Enterprises (OASES) of the Hong Kong Government; and over 20 representatives from various sectors in Hong Kong.

In the future, the joint venture will export products, technologies, and clinical services to international partners, driving the full-chain integration from basic research to clinical treatment and commercial application, thereby providing more innovative treatment options for patients in Hong Kong, Shenzhen, and globally.